Trump Health Secret Leak Shocks America

White House Rejects Claims Linking Trump to Eli Lilly Obesity Drug Through FDA “Compassionate Use” Program

The White House has pushed back strongly against online and media speculation suggesting that President Donald Trump may have been granted access to an experimental obesity medication through a federal emergency access pathway, calling the claims inaccurate and unfounded.

On Tuesday, officials dismissed a report alleging that Trump could have received retatrutide, an investigational weight-loss drug developed by Eli Lilly, through the Food and Drug Administration’s (FDA) “compassionate use” program. The program allows limited access to experimental treatments for patients with serious or life-threatening conditions when no approved alternatives are available.

The drug in question has not yet received FDA approval and remains in clinical testing. According to reporting cited in the controversy, a single patient was approved for access to the medication through the program, prompting speculation about the identity of the recipient.

That speculation intensified after anonymous sources told STAT News that the approved patient was 79 years old, leading to unfounded assumptions linking the case to Trump, who recently turned 80. However, White House officials firmly rejected any suggestion that the president was involved.

White House senior deputy press secretary Kush Desai publicly addressed the report on social media platform X, stating that the application had no connection to the president and criticizing the spread of unverified claims. He also pushed back on the reporting itself, arguing that it was based on speculation rather than confirmed information.

Desai further said the administration had not received or engaged in any application involving Trump and questioned the reasoning behind the assumptions made in the article. He added that it was inappropriate to extend speculation about a single anonymous case to millions of Americans within the same age group.

The White House and the Department of Health and Human Services reportedly did not respond to multiple inquiries from reporters asking whether the president had been prescribed or was using any weight-loss medications.

The discussion also comes amid ongoing public attention to Trump’s health and weight. A physical examination from last year listed his weight at approximately 224 pounds. In past interviews, including one with The New York Times, Trump has acknowledged that he has considered whether weight-loss medications might be appropriate for him but has not confirmed using them.

Separately, critics have occasionally pointed to Trump’s public appearances, including moments where he appeared fatigued during meetings, though no medical conclusions have been officially released linking such observations to any condition or treatment.

The patient referenced in the STAT News report was described as suffering from complex medical conditions, including obstructive sleep apnea and pulmonary hypertension. The request for retatrutide was reportedly submitted by a clinician at the National Institutes of Health, focusing on treatment for severe, treatment-resistant obesity.

According to medical literature referenced in federal health databases, such cases involve patients who have not achieved meaningful weight loss despite multiple therapeutic approaches, including behavioral interventions, medications, and supervised diet programs.

White House communications director Steven Cheung also responded sharply to the allegations, rejecting the reporting and criticizing the outlet for publishing what he described as unsupported conclusions. He accused reporters of amplifying speculation without sufficient verification.

The administration’s response underscores growing sensitivity around health-related misinformation involving high-profile political figures, particularly when experimental medical treatments and federal access programs are involved.